Seegene, Inc. (096530.KQ)
KRW 26500.0
(0.76%)
KRW 26500.0
(0.76%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 35.65 Billion KRW | -85.07% |
| 2022 | 280.07 Billion KRW | -66.02% |
| 2021 | 715.12 Billion KRW | 1.34% |
| 2020 | 693.63 Billion KRW | 2027.71% |
| 2019 | 32.6 Billion KRW | 81.04% |
| 2018 | 18 Billion KRW | 29.85% |
| 2017 | 10.99 Billion KRW | -16.65% |
| 2016 | 18.6 Billion KRW | 13.4% |
| 2015 | 14.67 Billion KRW | -12.56% |
| 2014 | 16.78 Billion KRW | -3.13% |
| 2013 | 17.32 Billion KRW | 1064.93% |
| 2012 | 14.2 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 3.14 Billion KRW | -39.02% |
| 2024 Q2 | 16.78 Billion KRW | 210.65% |
| 2023 Q2 | 6.85 Billion KRW | 241.53% |
| 2023 Q1 | 2 Billion KRW | -93.91% |
| 2023 FY | - KRW | -85.07% |
| 2023 Q4 | 20.3 Billion KRW | 212.73% |
| 2023 Q3 | 6.49 Billion KRW | -5.3% |
| 2022 Q3 | -33.43 Billion KRW | -223.71% |
| 2022 Q2 | 27.02 Billion KRW | -87.27% |
| 2022 Q4 | 32.96 Billion KRW | 198.6% |
| 2022 Q1 | 212.29 Billion KRW | -1.34% |
| 2022 FY | - KRW | -66.02% |
| 2021 Q1 | 200.98 Billion KRW | -23.49% |
| 2021 Q3 | 134.81 Billion KRW | -11.27% |
| 2021 FY | - KRW | 1.34% |
| 2021 Q4 | 215.17 Billion KRW | 59.6% |
| 2021 Q2 | 151.94 Billion KRW | -24.4% |
| 2020 Q1 | 42.88 Billion KRW | 417.63% |
| 2020 Q3 | 214.43 Billion KRW | 24.19% |
| 2020 Q4 | 262.68 Billion KRW | 22.5% |
| 2020 FY | - KRW | 2027.71% |
| 2020 Q2 | 172.67 Billion KRW | 302.63% |
| 2019 FY | - KRW | 81.04% |
| 2019 Q3 | 9.3 Billion KRW | 33.06% |
| 2019 Q4 | 8.28 Billion KRW | -10.95% |
| 2019 Q2 | 6.99 Billion KRW | -12.8% |
| 2019 Q1 | 8.01 Billion KRW | 17.77% |
| 2018 Q1 | 2.95 Billion KRW | -39.87% |
| 2018 FY | - KRW | 29.85% |
| 2018 Q4 | 6.8 Billion KRW | 41.8% |
| 2018 Q3 | 4.8 Billion KRW | 39.5% |
| 2018 Q2 | 3.44 Billion KRW | 16.47% |
| 2017 Q3 | 2.31 Billion KRW | 77.5% |
| 2017 Q2 | 1.3 Billion KRW | -75.92% |
| 2017 Q1 | 5.41 Billion KRW | 26.13% |
| 2017 Q4 | 4.91 Billion KRW | 112.23% |
| 2017 FY | - KRW | -16.65% |
| 2016 FY | - KRW | 13.4% |
| 2016 Q1 | 3.45 Billion KRW | -11.69% |
| 2016 Q2 | 4.35 Billion KRW | 26.04% |
| 2016 Q3 | 4.52 Billion KRW | 3.82% |
| 2016 Q4 | 4.29 Billion KRW | -5.08% |
| 2015 Q2 | 3.4 Billion KRW | -22.26% |
| 2015 Q1 | 4.38 Billion KRW | 23.36% |
| 2015 Q4 | 3.91 Billion KRW | 32.09% |
| 2015 FY | - KRW | -12.56% |
| 2015 Q3 | 2.96 Billion KRW | -12.99% |
| 2014 Q1 | 4.09 Billion KRW | -15.88% |
| 2014 FY | - KRW | -3.13% |
| 2014 Q4 | 3.55 Billion KRW | -10.82% |
| 2014 Q3 | 3.98 Billion KRW | -22.61% |
| 2014 Q2 | 5.14 Billion KRW | 25.77% |
| 2013 Q4 | 4.86 Billion KRW | -4.54% |
| 2013 Q2 | 4.32 Billion KRW | 42.95% |
| 2013 FY | - KRW | 1064.93% |
| 2013 Q3 | 5.09 Billion KRW | 17.74% |
| 2013 Q1 | 3.02 Billion KRW | 290.79% |
| 2012 Q4 | -1.58 Billion KRW | -2524.52% |
| 2012 Q3 | -60.49 Million KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 157.89 Billion KRW | 77.417% |
| InBody Co.,Ltd | 44.25 Billion KRW | 19.437% |
| Curexo Inc. | -2.75 Billion KRW | 1394.852% |
| i-SENS, Inc. | 24.14 Billion KRW | -47.674% |
| Ray Co., Ltd. | 7.62 Billion KRW | -367.665% |
| Gencurix Inc. | -18.09 Billion KRW | 297.071% |
| Sugentech Inc. | -12.13 Billion KRW | 393.911% |
| L&C Bio Co., Ltd | 13.4 Billion KRW | -166.042% |